The weekly litigation news digest is live. Subscribe now

IP Verse

Anticancer Compositions - EP3226843

The patent EP3226843 was granted to Aragon Pharmaceuticals on May 26, 2021. The application was filed on Dec 3, 2015 under application number EP15820351A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3226843

ARAGON PHARMACEUTICALS
Application Number
EP15820351A
Filing Date
Dec 3, 2015
Status
Opposition Rejected
Mar 21, 2025
Publication Date
May 26, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
TEVA PHARMACEUTICALSFeb 25, 2022D YOUNGADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2013184681
INTERNATIONAL-SEARCH-REPORTWO2013152342
INTERNATIONAL-SEARCH-REPORTWO2015118015
OPPOSITIONWO02080902
OPPOSITIONWO03063821
OPPOSITIONWO2013152342
OPPOSITIONWO2013184681
OPPOSITIONWO2014043208
OPPOSITIONWO2014113260

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents